新型带状疱疹重组亚单位疫苗Shingrix的研究进展

Progress in research on a novel recombinant varicella zoster virus subunit vaccine Shingrix

人类是水痘-带状疱疹病毒(varicella zoster virus,VZV)唯一的宿主,首次感染表现为水痘或呈隐性感染,病毒可延轴突上行,潜伏在感觉神经节内,通常终身潜伏,当机体免疫功能降低时,VZV可被重新激活,引发带状疱疹。Shingrix是一种新型带状疱疹重组亚单位疫苗,主要成分为重组VZV糖蛋白E(gE)和佐剂系统AS01B,美国FDA于2017年10月批准用于年龄≥50岁成年人带状疱疹的预防。Shingrix可有效强化VZV特异性免疫,预防带状疱疹及其并发症。本文对Shingrix的药理作用、适应证、用法用量、不良反应、特殊人群用药等内容作一综述。

Human being is the only host of varicella zoster virus (VZV). The first infection with the virus may cause varicella or is in latency,in which the virus may ascend along the axon and latent in the sensory ganglion,resulting in lifelong latency in general. When the immune function is depressed,VZV may be reactivated and result in zoster. Shingrix is a novel recombinant subunit vaccine containing VZV glycoprotein E and the AS01B adjuvant system,which was approved by the FDA in October 2017 for the prevention of herpes zoster in adults at ages of not less than 50 years. Shingrix can effectively strengthen the specific immunity of VZV and prevent varicella zoster as well its complication. This paper reviews the pharmacology,indications,usage and dosage as well as adverse reactions and administration in specific populations of Shingrix.